{"id":"paclitaxel-or-docetaxel-or-irinotecan","safety":{"commonSideEffects":[{"rate":"40-90","effect":"Neutropenia"},{"rate":"30-80","effect":"Anemia"},{"rate":"20-50","effect":"Thrombocytopenia"},{"rate":"20-60","effect":"Peripheral neuropathy"},{"rate":"30-70","effect":"Nausea/vomiting"},{"rate":"20-80","effect":"Diarrhea"},{"rate":"20-80","effect":"Alopecia"},{"rate":"30-70","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3989514","moleculeType":"Small molecule","molecularWeight":"677.19"},"_fixedAt":"2026-03-30T11:59:24.009981","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel and docetaxel are microtubule-stabilizing agents that prevent microtubule depolymerization, disrupting mitotic spindle formation and cell cycle progression. Irinotecan is a topoisomerase I inhibitor that prevents DNA religation, causing DNA damage and cell death. All three are broad-spectrum chemotherapeutics used across multiple solid tumors.","oneSentence":"These taxane and camptothecin chemotherapy agents stabilize microtubules or inhibit topoisomerase I to disrupt cell division and induce apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:25.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Gastric cancer"},{"name":"Colorectal cancer"}]},"_fixedFields":["pubmed(79092)"],"trialDetails":[{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT07487896","phase":"PHASE3","title":"A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-04-30","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":440},{"nctId":"NCT07463573","phase":"PHASE3","title":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-05","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":466},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT07417735","phase":"PHASE3","title":"SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-03-18","conditions":"Locally Advanced/Metastatic/Recurrent ESCC","enrollment":436},{"nctId":"NCT07284134","phase":"PHASE3","title":"JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-12-24","conditions":"Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":560},{"nctId":"NCT06644781","phase":"PHASE3","title":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":510},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06304974","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":497},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT05381038","phase":"PHASE1, PHASE2","title":"Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-02-13","conditions":"Solid Tumor, Gastrointestinal Cancer, Breast Cancer","enrollment":10},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT06769425","phase":"PHASE1","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-07","conditions":"Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer","enrollment":157},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT05800587","phase":"PHASE2","title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-02-22","conditions":"Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT06745193","phase":"PHASE2","title":"A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-02-01","conditions":"Advanced Esophageal Carcinoma","enrollment":63},{"nctId":"NCT06649292","phase":"PHASE3","title":"SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-22","conditions":"Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":524},{"nctId":"NCT03430843","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-01-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":512},{"nctId":"NCT03904927","phase":"PHASE2","title":"Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-02-01","conditions":"Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","enrollment":104},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT06190782","phase":"PHASE3","title":"Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-27","conditions":"Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy","enrollment":354},{"nctId":"NCT06123494","phase":"PHASE3","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-09","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":360},{"nctId":"NCT05427383","phase":"PHASE2, PHASE3","title":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-04-07","conditions":"Stomach Cancer","enrollment":286},{"nctId":"NCT03933449","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-12-29","conditions":"Esophageal Carcinoma, Esophagogastric Junction Carcinoma","enrollment":123},{"nctId":"NCT02564263","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-01","conditions":"Esophageal Carcinoma, Esophagogastric Junction Carcinoma","enrollment":628},{"nctId":"NCT05649163","phase":"","title":"Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy","status":"UNKNOWN","sponsor":"Shen Lin","startDate":"2023-01","conditions":"HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":306},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130},{"nctId":"NCT05320874","phase":"PHASE1","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-04","conditions":"Advanced Solid Tumor","enrollment":232},{"nctId":"NCT05322499","phase":"PHASE2","title":"Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-04-15","conditions":"Stage IV Esophagus Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT01822613","phase":"PHASE1","title":"Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-26","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":48},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT03668418","phase":"","title":"Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2018-06-01","conditions":"Liver Cancer, Pancreatic Cancer, Gastric Cancer","enrollment":120},{"nctId":"NCT01188499","phase":"PHASE1, PHASE2","title":"Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"TetraLogic Pharmaceuticals","startDate":"2010-10","conditions":"Cancer","enrollment":176},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00476827","phase":"PHASE2","title":"A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-05","conditions":"Breast Cancer","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79092,"recentPublications":[{"date":"2026 Mar 27","pmid":"41906744","title":"Lipid Nanoparticle Encapsulated Chemotherapeutic Drugs Quantitation In vivo using Liquid Chromatography-coupled Electrospray Ionization Tandem Mass Spectrometry.","journal":"Journal of physiological investigation"},{"date":"2026 Mar 29","pmid":"41906410","title":"UGT1A1 Fragment Analysis: Genotyping the (TA)(n) Variable Repeat Polymorphism for Clinical Applications.","journal":"Journal of clinical laboratory analysis"},{"date":"2026","pmid":"41905949","title":"Establishment of Irinotecan-Induced Oral Mucositis Hamster Model and Evaluation of Therapeutic Agents.","journal":"Biological & pharmaceutical bulletin"},{"date":"2026 Mar 27","pmid":"41905580","title":"Target Vessel Binary Re-stenosis following the Use of Paclitaxel Coated Versus Uncoated Devices during Infrainguinal Endovascular Revascularisation of Symptomatic Peripheral Arterial Disease: Exploratory Data from the SWEDEPAD 1 and 2 Trials.","journal":"European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery"},{"date":"2026 Mar 27","pmid":"41905502","title":"Selenium Attenuates Paclitaxel-Induced Peripheral Neuropathy by Suppressing Oxidative Stress, Inflammation, and Apoptosis in Rat Sciatic Nerve.","journal":"Neurotoxicology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel or docetaxel or irinotecan","genericName":"Paclitaxel or docetaxel or irinotecan","companyName":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","companyId":"shanghai-runshi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These taxane and camptothecin chemotherapy agents stabilize microtubules or inhibit topoisomerase I to disrupt cell division and induce apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}